Anavex Life Sciences Corp. (AVXL)

$3.73

-0.04

(-1.06%)

Market is closed - opens 7 PM, 18 Jun 2024

Insights on Anavex Life Sciences Corp.

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 76.7% return, outperforming this stock by 132.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 244.3% return, outperforming this stock by 326.5%

Performance

  • $3.66
    $3.75
    $3.73
    downward going graph

    1.88%

    Downside

    Day's Volatility :2.4%

    Upside

    0.53%

    downward going graph
  • $3.25
    $10.45
    $3.73
    downward going graph

    12.87%

    Downside

    52 Weeks Volatility :68.9%

    Upside

    64.31%

    downward going graph

Returns

PeriodAnavex Life Sciences Corp.Sector (Health Care)Index (Russel 2000)
3 Months
-21.78%
0.4%
0.0%
6 Months
-57.11%
8.7%
0.0%
1 Year
-55.17%
10.3%
0.0%
3 Years
-82.24%
16.5%
-22.7%

Highlights

Market Capitalization
319.1M
Book Value
$1.61
Earnings Per Share (EPS)
-0.5
PEG Ratio
0.0
Wall Street Target Price
27.5
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-19.63%
Return On Equity TTM
-28.98%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
Diluted Eps TTM
-0.5
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.52
EPS Estimate Next Year
-0.64
EPS Estimate Current Quarter
-0.11
EPS Estimate Next Quarter
-0.12

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Anavex Life Sciences Corp.(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 637.27%

Current $3.73
Target $27.50

Technicals Summary

Sell

Neutral

Buy

Anavex Life Sciences Corp. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Anavex Life Sciences Corp.
Anavex Life Sciences Corp.
-17.14%
-57.11%
-55.17%
-82.24%
20.06%
Moderna, Inc.
Moderna, Inc.
5.36%
63.93%
12.72%
-30.84%
787.95%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.52%
21.82%
32.68%
93.38%
233.31%
Novo Nordisk A/s
Novo Nordisk A/s
8.04%
43.97%
76.29%
244.33%
458.71%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
7.98%
18.8%
40.28%
155.22%
176.63%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Anavex Life Sciences Corp.
Anavex Life Sciences Corp.
NA
NA
0.0
-0.52
-0.29
-0.2
NA
1.61
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.71
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.32
30.32
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.73
49.73
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.07
31.07
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Anavex Life Sciences Corp.
Anavex Life Sciences Corp.
Buy
$319.1M
20.06%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$55.7B
787.95%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$113.1B
233.31%
30.32
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$634.9B
458.71%
49.73
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$123.6B
176.63%
31.07
39.46%

Institutional Holdings

  • State Street Corporation

    8.62%
  • BlackRock Inc

    7.85%
  • Vanguard Group Inc

    5.22%
  • Geode Capital Management, LLC

    2.02%
  • Bank of America Corp

    1.01%
  • Nwam, LLC

    0.99%

Company Information

anavex life sciences corp. is a clinical stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodevelopmental and neurodegenerative diseases. anavex is currently in a phase 2a trial for alzheimer's disease (ad) with lead therapeutic, anavex 2-73, an orally available small molecule targeting protein misfolding and cellular stress through activating the sigma-1 receptor. part a topline data of our ongoing phase 2a trial demonstrate a favorable safety, bioavailability, dose-response curve and tolerability/risk profile. anavex 2-73 is a potential platform drug showing encouraging preclinical data rare neurodevelopmental disease: rett syndrome, as well is in epilepsy and multiple sclerosis (ms). in 2015, the company was awarded a research by the michael j. fox foundation (mjff) to study anavex 2-73 for the treatment of parkinson’s disease. headquartered in new york, anavex is an american publicly traded corporation quoted as avxl.

Organization
Anavex Life Sciences Corp.
Employees
40
CEO
Dr. Christopher U. Missling M.B.A., M.S., Ph.D.
Industry
Health Technology

FAQs